Zydus Cadila and Prolong Pharma sign drug discovery collaboration

The Zydus-Prolong agreement seeks to increase productivity in the drug development of this next generation therapeutic protein by leveraging the combined strengths of both companies. Under the terms of the agreement, both companies will utilize Prolong’s differentiated PEGylation technology to make PEG-EPO. This joint development will help in developing an optimized drug candidate with improved therapeutic properties. Both partners will also be equitably sharing risk and reward for this collaborative program.

Zydus Cadila will leverage its expertise in carrying out a focused drug development program, starting from preclinical candidate selection, filing of the investigational new drug, undertaking preclinical studies and human clinical trials and marketing it in mutually agreed upon territories globally.

Abe Abuchowski, president and COO of Prolong, said: “This collaboration will also enable Prolong to capitalize on the cost effective drug development capabilities that India offers.”